| خلاصه مقاله | Introduction and background: Verapamil is L-type calcium channel blocker widely used in the treatment of angina, arrhythmia, hypertension, cardiomyopathies, cluster headaches and modifying agent in tumors. It is necessary for future individualized patient treatment to develop a simple, rapid and highly sensitive method for the monitoring of verapamil doses in biological fluids. Exhaled breath condensate (EBC) sampling, as a fairly easily accessible matrix, is easy, repeatable, unassociated with side effects and any appreciable discomfort or risk to the subject. The assay method is based on using of a rigidity–induced material which eliminated collisional quenching and vibrational modes responsible for nonradiative decay. This process produced an enhancement in the emission intensity of verapamil, which made it possible to develop a sensitive bioanalytical methodologies for direct verapamil quantification in biological fluids.
Methods: An aliquot of EBC sample solution containing verapamil was transferred into a 2 ml vial, 80 µl of SDS solution was added. The solution was diluted with deionized water to 0.5 ml and mixed well. After 15 min the fluorescence intensity was measured at 310 nm with excitation at 280 nm.
Results: The important parameters influencing the analytical signal in experimental steps were investigated and optimized. Under the optimized experimental conditions, the calibration graph was linear in the range of 0.02−12.00 µg.mL−1 with a detection limit of 0.008 µg.mL−1.
Discussion and Conclusion: In this research, we reported an enhanced fluorimetric assay for the direct monitoring of verapamil in exhaled breath condensate. Advantages of this method is utilizing a simple fluorimetery detection include the minimal time required to analyze samples without any sample preparation steps. The obtained sensitivity is adequate for single dose pharmacokinetic studies to be properly performed. |